Briumvi (ublituximab-xiiy)
$15,132.53
This medicine requires a prescription. See “Prescription Guide”.
We can only help if the medicine is not available in your country. Learn more.
Buy Briumvi (ublituximab-xiiy)
What is Briumvi (ublituximab-xiiy) for?
Briumvi (ublituximab-xiiy) is a prescription medicine used to treat adult patients with Multiple Sclerosis (MS) presenting relapsing forms of this pathology as[1]:
- Clinically isolated syndrome (CIS).
- Active secondary progressive disease.
- Relapsing-remitting disease.
How does Briumvi (ublituximab-xiiy) work?
Briumvi (ublituximab-xiiy) produces cellular cytolysis of the B Lympochites through antibody-dependent and complement-dependent mechanisms. It is assumed that Briumvi (ublituximab-xiiy) binds with the CD20 present on the surface of the B Lympochites, causing the lysis[1].
Where has Briumvi (ublituximab-xiiy) been approved?
The FDA approved Briumvi (ublituximab-xiiy) in the USA in December 2022[2].
References
- Full prescribing information [FDA]: Briumvi (ublituximab-xiiy) [PDF] TG Therapeutics, inc. December 2022.
- Press Release: TG Therapeutics announce the FDA approval for Briumvi (ublituximab-xiiy)
TG Therapeutics, inc. December 2022
| single-dose vial x 150 mg/6 mL (25 mg/mL) | 15,132.53 |
|---|
Be the first to review “Briumvi (ublituximab-xiiy)”
Related products
Amyotrophic Lateral Sclerosis (ALS)
Multiple Sclerosis (MS)
Duchenne Muscular Dystrophy
Amyotrophic Lateral Sclerosis (ALS)
Multiple Sclerosis (MS)
Migraine
Alzheimer's disease
Multiple Sclerosis (MS)
Reviews
There are no reviews yet.